Skip to main content
Publish date:

Tuesday's Health Winners & Losers

OSI Pharmaceuticals is higher.
Author:

OSI Pharmaceuticals

(OSIP)

reported a wider net loss in the third quarter and announced plans to exit the eye business, saying it won't reach the goals it set when it acquired Eyetech Pharmaceuticals last year.

Shares of OSI rose 2.1% to $39.60.

"It is evident that a key strategic goal behind our acquisition of Eyetech -- that of generating positive cash flow from the eye business in the 2006-2008 period -- will not be realized," said OSI Chief Executive Colin Goddard.

Shares of

Targeted Genetics

(TGEN) - Get Tecogen Inc. Report

got a boost after it said

Biogen Idec

(BIIB) - Get Biogen Inc. Report

is increasing its stake in the company to 19.9%.

Targeted Genetics saw its stock jump 75 cents, or 35%, to $2.90.

Novartis

TheStreet Recommends

(NVS) - Get Novartis AG Sponsored ADR Report

edged higher after receiving European Union approval to sell an arthritis drug that belongs to the same class as

Merck's

(MRK) - Get Merck & Co., Inc. (MRK) Report

Vioxx and

Pfizer's

(PFE) - Get Pfizer Inc. Report

Celebrex.

The Novartis drug, Prexige, has already been cleared in more than two dozen countries, including the U.K. and Canada. The decision by EU regulators means the drug will be available in all 26 member nations in 2007 or 2008, Novartis says. In the EU, Prexige can be sold to treat osteoarthritis, or the degeneration of the joints, in the knee and hip. Novartis was up 2 cents to $61.25.

Teva Pharmaceutical Industries

(TEVA) - Get Teva Pharmaceutical Industries Limited Sponsored ADR Report

, the world's biggest maker of generic drugs, said third-quarter sales surged 74% year over year, after including the results from the acquisition of Ivax.

Revenue for the third quarter totaled $2.29 billion, up from $1.32 billion a year ago. Net income more than doubled, rising to $606 million from $267 million last year. Earnings per share advanced to 74 cents from 40 cents in the 2005 third quarter.

Analysts surveyed by Thomson Financial were expecting a profit of 63 cents and sales of $2.33 billion. Shares of Teva fell 2.2% to $32.56.